USPTO Extends CARES Act Deadline Relief

05 May 2020 Blog
Authors: Courtenay C. Brinckerhoff
Published To: PharmaPatents Coronavirus Resource Center:Back to Business PTAB Trial Insights

The United States Patent and Trademark Office (USPTO) has extended the period for deferring certain deadlines under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The relief still applies only to those “personally affected by the COVID-19 outbreak,” but now affected applicants and patent owners can defer certain deadlines until June 1, 2020. The USPTO also has released a new form with the language for the required statement that the delay was due to the COVID-19 outbreak. 

Deferring Patent Office Deadlines Under the CARES Act

As reported in this article, Section 12004 of the CARES Act granted the USPTO temporary authority to extend statutory deadlines. The USPTO’s original notice issued March 31, 2020, explained how the agency is exercising that authority for patent-related deadlines, which deadlines can be deferred, and what applicants need to do to obtain relief. As explained in this article, practitioners and stakeholders should note that (1) only certain deadlines are eligible for this relief, (2) only certain parties are eligible to claim this relief, and (3) some requests for extensions of deadlines in PTAB proceedings may need to be made in advance. 

The April 28 notice supersedes the March 31 notice and makes a few changes. Most of the substantive details are the same, except for provisions pertaining to deadlines in PTAB proceedings. Deadlines for a request for rehearing of a PTAB decision under 37 C.F.R. §§ 41.125(c), 41.127(d), or 42.71(d) or a petition to the Chief Judge under 37 C.F.R. § 41.3 no longer require a “request” if the filing is accompanied by the required statement that the delay in filing was due to the COVID-19 outbreak. On the other hand, it appears that deadlines for a patent owner preliminary response falling after April 30 only can be deferred under the “additional relief” protocol that requires a specific request and case-by-case approval. 

Reviving Abandoned Applications Without A Fee

The April 28 notice also revises the relief pertaining to applications that became abandoned “as a result of the COVID-19 outbreak,” originally discussed in this article. Now, this relief is limited to eligible applications and reexamination proceedings that became abandoned (or terminated or limited) on or before May 31, 2020, as a result of the COVID-19 outbreak. This notice also “harmonizes the statement that must be provided” to take advantage of the revival fee relief to be the same as that required for the CARES Act deadline relief.

The revival fee relief is available to “applicants or patent owners who, because of the COVID-19 outbreak, were unable to timely submit a filing or payment ... having a due date of May 31, 2020, or earlier (when taking into account all available extensions of time under 37 C.F.R. 1.136(a)).” The USPTO will “waive the petition [to revive] fee in 37 C.F.R. § 1.l 7(m)” if the petition is accompanied by the required statement that the delay in filing or payment was “due to the COVID-19 outbreak,” i.e., that “a practitioner, applicant, patent owner, petitioner, third party requester, inventor, or other person associated with the filing or fee was personally affected by the COVID-19 outbreak, including, without limitation, through office closures, cash flow interruptions, inaccessibility of files or other materials, travel delays, personal or family illness, or similar circumstances, such that the outbreak materially interfered with timely filing or payment.”

The notice urges applicants and patent owners to seek revival “promptly,” and notes that document code PET.RELIEF can be used for submissions via the USPTO’s patent electronic filing systems (EFS-Web or Patent Center).

Answering Questions About COVID-19 Relief

The USPTO prefers that questions about these COVID-19 relief programs be emailed to Covid19PatentsRelief@uspto.gov. The USPTO also has a CARES ACT Frequently Asked Question page that soon will be updated in view of the April 28 notice. 

Foley has created a multi-disciplinary and multi-jurisdictional team, which has prepared a wealth of topical client resources and is prepared to help our clients meet the legal and business challenges that the coronavirus outbreak is creating for stakeholders across a range of industries. Click here for Foley’s Coronavirus Resource Center to stay apprised of relevant developments, insights and resources to support your business during this challenging time. To receive this content directly in your inbox, click here and submit the form.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Insights